Business Context and Reporting Period
Company: A SPAC III Acquisition Corp. (ASPCU/ASPC/ASPCR)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Model: A blank check company (SPAC) incorporated in the British Virgin Islands, formed to effect a merger or business combination with one or more target businesses, primarily in the ESG and material technology sectors.
Status: Pre-business combination. The company has not commenced operations other than organizational activities and searching for a target.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Income (Loss) | $1,343,931 | $(226,383) |
| Operating Expenses | $827,300 | $587,106 |
| Interest Income (Trust Account) | $2,171,231 | $360,723 |
| Cash and Cash Equivalents (Outside Trust) | $871,350 | $1,598,890 |
| Investments Held in Trust Account | $2,979,936 | $60,356,959 |
| Working Capital | $419,761 | $1,200,865 |
| Debt (Promissory Note) | $0 | $276,221 |
Note: The significant decrease in Trust Account assets in 2025 is due to shareholder redemptions described below.
Material Changes vs. Prior Period
- Shareholder Redemptions: In connection with a shareholder vote to extend the business combination deadline, 5,717,419 Class A ordinary shares were redeemed for approximately $59.5 million. This reduced the Trust Account balance from ~$60.4 million to ~$3.0 million.
- Extension of Combination Period: Shareholders approved an amendment to extend the deadline to consummate a business combination from November 12, 2025, to November 12, 2026 (24 months from IPO).
- Profitability Shift: The company reported a net income of $1.34 million in 2025 compared to a net loss of $0.23 million in 2024, driven primarily by higher interest income earned on the Trust Account prior to redemptions.
- Target Agreement: Entered into a Merger Agreement with Bioserica International Limited (a bio-based antimicrobial materials company) in May 2025. A prior agreement with HDEducation Group was terminated in May 2025.
Guidance, Outlook, and Risks
- Merger Agreement: The proposed merger with Bioserica values the target at approximately $217.9 million. The transaction is subject to customary closing conditions and shareholder approval.
- Going Concern: Management has determined that the company's ability to continue as a going concern is raised in substantial doubt due to the requirement to complete a business combination by November 12, 2026, or liquidate. The financial statements do not include adjustments that might result from this uncertainty.
- Liquidity: The company holds approximately $871,000 in cash outside the Trust Account. It may rely on working capital loans from the Sponsor (up to $1.15 million convertible) to fund operations and transaction costs.
- China Regulatory Risks: Significant risks are associated with the potential acquisition of a target with operations in China, including regulatory reviews (CSRC, cybersecurity), VIE structure uncertainties, and potential restrictions on foreign ownership or capital repatriation.
- HFCAA Compliance: Risks exist regarding the Holding Foreign Companies Accountable Act if the target's auditor cannot be inspected by the PCAOB, which could lead to delisting.
Investor Verification Checklist
- Merger Status: Verify the current status of the Bioserica Merger Agreement and whether all closing conditions have been met.
- Redemption Impact: Confirm the remaining cash in the Trust Account ($2.98M) is sufficient to cover the pro-rata redemption value for remaining public shares if the deal fails or is amended.
- Sponsor Ownership: Note that the Sponsor holds approximately 76.4% of outstanding shares following redemptions and a subsequent share exchange in January 2026.
- Going Concern: Assess the likelihood of the company raising additional capital or completing the merger before the November 2026 deadline to avoid mandatory liquidation.
- China Exposure: Evaluate the specific regulatory hurdles for Bioserica's operations in China and the enforceability of any VIE structures.